Skip to content

LONA LONA Operating lease liabilities

Operating lease liabilities at other companies

Arvinas logo
ArvinasARVN
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Immunome logo
ImmunomeIMNM

Other financials

Income statement

See full
Operating income-$17.2M-80.5%
Net income-$32.9M-260%
EPS (diluted)-$1.73+26.1%

Balance sheet

See full
Cash & equivalents$32.8M+24.3%
Total debt$691.0K-38.2%
Total equity$49.3M+32.1%
Total assets$71.6M+64.5%

Cash flow

See full
Operating cash flow-$20.9M-42.5%
CapEx$28.0K-15.2%
Free cash flow-$26.0M+1.1%

Valuation

See full
Market cap$86.33M+223%
Enterprise value$54.18M

Returns & leverage

See full
Return on equity-298.8%-726pp
Debt / equity0.0×
Current ratio10.4×+3.1×

Where this comes from

Reported directly by LONA in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: LONA’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about LONA's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LONA's operating lease liabilities?
LONA (LONA) reported operating lease liabilities of -$112K in Q1 2026.
How has LONA's operating lease liabilities changed year-over-year?
LONA's operating lease liabilities decreased by 12.0% year-over-year, from -$100K to -$112K.
What is the long-term trend for LONA's operating lease liabilities?
Over 2 years (2023 to 2025), LONA's operating lease liabilities has grown at a 12.7% compound annual growth rate (CAGR), from -$326K to -$414K.